You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Anasys Instruments Corp. Topic: 300
DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: 101
DESCRIPTION provided by applicant Up to of low birth weight preterm infants manifest some form of periventricular white matter injury PWMI making it the most common form of brain injury affecting premature infants In the US infants per year are born at risk for PWMI and about children per year will develop PWMI World wide infants will be born each year at ri ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: 104
DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: AGILE HEALTH INC Topic: NIMHD
DESCRIPTION provided by applicant Latinos Kick Buts Mobile Engagement and Cessation Support for Latino Smokers Latinos are less likely than non Hispanic whites to have access to health to have knowledge of existing smoking cessation resources to receive advice to stop smoking and to participate in smoking cessation programs Mobile technologies can dramatically enhance the reach of effectiv ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: NIAID
DESCRIPTION provided by applicant Multiple sclerosis MS is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults affecting over patients in the US and over million patients worldwide MS is a disease of high unmet medical need currently treatable with one of twelve FDA approved drugs all of which result in either significant i ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Surface Bioadvances, Inc. Topic: NIAMS
DESCRIPTION provided by applicant Dysbiosis refers to a condition with microbial imbalances within the human microbiome Yogurts are the best examples of using fermenting gut bacteria to rebalance the gut dysbiosis Our results demonstrate for the first time that Staphylococcus epidermidis S epidermidis a commensal bacterium of the human skin functions as a probiotic microorganism that em ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: MICROBIOTIX, INC. Topic: R
DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: NIAID
DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ABREOS BIOSCIENCES, INC. Topic: NIAMS
DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: NERX BIOSCIENCES, INC. Topic: NCI
DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health